These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 33441554)

  • 1. Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.
    Gromeier M; Brown MC; Zhang G; Lin X; Chen Y; Wei Z; Beaubier N; Yan H; He Y; Desjardins A; Herndon JE; Varn FS; Verhaak RG; Zhao J; Bolognesi DP; Friedman AH; Friedman HS; McSherry F; Muscat AM; Lipp ES; Nair SK; Khasraw M; Peters KB; Randazzo D; Sampson JH; McLendon RE; Bigner DD; Ashley DM
    Nat Commun; 2021 Jan; 12(1):352. PubMed ID: 33441554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study.
    Miller KE; Cassady KA; Roth JC; Clements J; Schieffer KM; Leraas K; Miller AR; Prasad N; Leavenworth JW; Aban IB; Whitley RJ; Gillespie GY; Mardis ER; Markert JM
    Clin Cancer Res; 2022 Feb; 28(3):498-506. PubMed ID: 35105718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent Glioblastoma-Molecular Underpinnings and Evolving Treatment Paradigms.
    Chang C; Chavarro VS; Gerstl JVE; Blitz SE; Spanehl L; Dubinski D; Valdes PA; Tran LN; Gupta S; Esposito L; Mazzetti D; Gessler FA; Arnaout O; Smith TR; Friedman GK; Peruzzi P; Bernstock JD
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomics and proteomics to determine novel molecular subtypes and predict the response to immunotherapy and the effect of bevacizumab in glioblastoma.
    Luo D; Luo A; Hu S; Ye G; Li D; Zhao H; Peng B
    Sci Rep; 2024 Jul; 14(1):17630. PubMed ID: 39085480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Genomic Sequencing Reveals Different Evolutionary Patterns Between Locally and Distally Recurrent Glioblastomas.
    Yoon N; Kim HS; Lee JW; Lee EJ; Maeng LS; Yoon WS
    Cancer Genomics Proteomics; 2020; 17(6):803-812. PubMed ID: 33099481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics.
    Li R; Chen X; You Y; Wang X; Liu Y; Hu Q; Yan W
    Oncotarget; 2015 Oct; 6(31):30968-74. PubMed ID: 26427041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model.
    Alessandrini F; Menotti L; Avitabile E; Appolloni I; Ceresa D; Marubbi D; Campadelli-Fiume G; Malatesta P
    Oncogene; 2019 Jun; 38(23):4467-4479. PubMed ID: 30755732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual?
    Chiocca EA; Nassiri F; Wang J; Peruzzi P; Zadeh G
    Neuro Oncol; 2019 Jan; 21(1):14-25. PubMed ID: 30346600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant Poliovirus for Cancer Immunotherapy.
    Gromeier M; Nair SK
    Annu Rev Med; 2018 Jan; 69():289-299. PubMed ID: 29414253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of glioblastoma: State of the art and future directions.
    Tan AC; Ashley DM; López GY; Malinzak M; Friedman HS; Khasraw M
    CA Cancer J Clin; 2020 Jul; 70(4):299-312. PubMed ID: 32478924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging therapies for glioblastoma: current state and future directions.
    Rong L; Li N; Zhang Z
    J Exp Clin Cancer Res; 2022 Apr; 41(1):142. PubMed ID: 35428347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent Glioblastomas Reveal Molecular Subtypes Associated with Mechanistic Implications of Drug-Resistance.
    Kwon SM; Kang SH; Park CK; Jung S; Park ES; Lee JS; Kim SH; Woo HG
    PLoS One; 2015; 10(10):e0140528. PubMed ID: 26466313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in
    Felsberg J; Hentschel B; Kaulich K; Gramatzki D; Zacher A; Malzkorn B; Kamp M; Sabel M; Simon M; Westphal M; Schackert G; Tonn JC; Pietsch T; von Deimling A; Loeffler M; Reifenberger G; Weller M;
    Clin Cancer Res; 2017 Nov; 23(22):6846-6855. PubMed ID: 28855349
    [No Abstract]   [Full Text] [Related]  

  • 15. How We Treat Recurrent Glioblastoma Today and Current Evidence.
    Chaul-Barbosa C; Marques DF
    Curr Oncol Rep; 2019 Oct; 21(10):94. PubMed ID: 31606796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction of Interferon-Gamma-Related Gene Signature to Characterize the Immune-Inflamed Phenotype of Glioblastoma and Predict Prognosis, Efficacy of Immunotherapy and Radiotherapy.
    Ji H; Ba Y; Ma S; Hou K; Mi S; Gao X; Jin J; Gong Q; Liu T; Wang F; Liu Z; Li S; Du J; Hu S
    Front Immunol; 2021; 12():729359. PubMed ID: 34566988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Microenvironment Characterization in Glioblastoma Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures.
    Zhang J; Xiao X; Zhang X; Hua W
    J Mol Neurosci; 2020 May; 70(5):738-750. PubMed ID: 32006162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Copy number profiling across glioblastoma populations has implications for clinical trial design.
    Cimino PJ; McFerrin L; Wirsching HG; Arora S; Bolouri H; Rabadan R; Weller M; Holland EC
    Neuro Oncol; 2018 Sep; 20(10):1368-1373. PubMed ID: 29982740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
    Maxwell R; Jackson CM; Lim M
    Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma.
    Qin L; Li X; Stroiney A; Qu J; Helgager J; Reardon DA; Young GS
    Neuroradiology; 2017 Feb; 59(2):135-145. PubMed ID: 28070598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.